Literature DB >> 17072955

Effect of transforming growth factor-beta1 on human intrahepatic cholangiocarcinoma cell growth.

Tetsuya Shimizu1, Shigeki Yokomuro, Yoshiaki Mizuguchi, Yutaka Kawahigashi, Yasuo Arima, Nobuhiko Taniai, Yasuhiro Mamada, Hiroshi Yoshida, Koho Akimaru, Takashi Tajiri.   

Abstract

AIM: To elucidate the biological effects of transforming growth factor-beta1 (TGF-beta1) on intrahepatic cholan-giocarcinoma (ICC).
METHODS: We investigated the effects of TGF-beta1 on human ICC cell lines (HuCCT1, MEC, and HuH-28) by monitoring the influence of TGF-beta1 on tumor growth and interleukin-6 (IL-6) expression in ICC cells.
RESULTS: All three human ICC cell lines produced TGF-beta1 and demonstrated accelerated growth in the presence of TGF-beta1 with no apoptotic effect. Studies on HuCCT1 revealed a TGF-beta1-induced stimulation of the expression of TGF-beta1, as well as a decrease in TGF-beta1 mRNA expression induced by neutralizing anti-TGF-beta1 antibody. These results indicate that TGF-beta1 stimulates the production and function of TGF-beta1 in an autocrine fashion. Further, IL-6 secretion was observed in all three cell lines and exhibited an inhibitory response to neutralizing anti-TGF-beta1 antibody. Experiments using HuCCT1 revealed a TGF-beta1-induced acceleration of IL-6 protein expression and mRNA levels. These findings demonstrate a functional interaction between TGF-beta1 and IL-6. All three cell lines proliferated in the presence of IL-6. In contrast, TGF-beta1 induced no growth effect in HuCCT1 in the presence of small interfering RNA against a specific cell surface receptor of IL-6 and signal transducer and activator of transcription-3.
CONCLUSION: ICC cells produce TGF-beta1 and confer a TGF-beta1-induced growth effect in an autocrine fashion. TGF-beta1 activates IL-6 production, and the functional interaction between TGF-beta1 and IL-6 contributes to ICC cell growth by TGF-beta1.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17072955      PMCID: PMC4088140          DOI: 10.3748/wjg.v12.i39.6316

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  42 in total

Review 1.  TGFbeta signaling in growth control, cancer, and heritable disorders.

Authors:  J Massagué; S W Blain; R S Lo
Journal:  Cell       Date:  2000-10-13       Impact factor: 41.582

Review 2.  Transforming growth factor beta and the liver.

Authors:  D M Bissell; D Roulot; J George
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

3.  Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States.

Authors:  T Patel
Journal:  Hepatology       Date:  2001-06       Impact factor: 17.425

4.  Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line.

Authors:  J Park; L Tadlock; G J Gores; T Patel
Journal:  Hepatology       Date:  1999-11       Impact factor: 17.425

5.  Dose-dependent inhibition of hepatic fibrosis in mice by a TGF-beta soluble receptor: implications for antifibrotic therapy.

Authors:  Yutaka Yata; Philip Gotwals; Victor Koteliansky; Don C Rockey
Journal:  Hepatology       Date:  2002-05       Impact factor: 17.425

6.  The effect of interleukin-6 (IL-6)/gp130 signalling on biliary epithelial cell growth, in vitro.

Authors:  S Yokomuro; J G Lunz; T Sakamoto; T Ezure; N Murase; A J Demetris
Journal:  Cytokine       Date:  2000-06       Impact factor: 3.861

7.  Transforming growth factor beta and activin tonically inhibit DNA synthesis in the rat liver.

Authors:  T Ichikawa; Y Q Zhang; K Kogure; Y Hasegawa; H Takagi; M Mori; I Kojima
Journal:  Hepatology       Date:  2001-11       Impact factor: 17.425

8.  Growth control of human biliary epithelial cells by interleukin 6, hepatocyte growth factor, transforming growth factor beta1, and activin A: comparison of a cholangiocarcinoma cell line with primary cultures of non-neoplastic biliary epithelial cells.

Authors:  S Yokomuro; H Tsuji; J G Lunz; T Sakamoto; T Ezure; N Murase; A J Demetris
Journal:  Hepatology       Date:  2000-07       Impact factor: 17.425

9.  Marked elevation of serum interleukin-6 in patients with cholangiocarcinoma: validation of utility as a clinical marker.

Authors:  J S Goydos; A M Brumfield; E Frezza; A Booth; M T Lotze; S E Carty
Journal:  Ann Surg       Date:  1998-03       Impact factor: 12.969

10.  The development and compensation of biliary cirrhosis in interleukin-6-deficient mice.

Authors:  T Ezure; T Sakamoto; H Tsuji; J G Lunz; N Murase; J J Fung; A J Demetris
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

View more
  11 in total

Review 1.  JAK-STAT pathway in carcinogenesis: is it relevant to cholangiocarcinoma progression?

Authors:  Olga V Smirnova; Tatiana Yu Ostroukhova; Roman L Bogorad
Journal:  World J Gastroenterol       Date:  2007-12-28       Impact factor: 5.742

2.  Transforming Growth Factors α and β Are Essential for Modeling Cholangiocarcinoma Desmoplasia and Progression in a Three-Dimensional Organotypic Culture Model.

Authors:  Miguel Á Manzanares; Akihiro Usui; Deanna J Campbell; Catherine I Dumur; Gabrielle T Maldonado; Michel Fausther; Jonathan A Dranoff; Alphonse E Sirica
Journal:  Am J Pathol       Date:  2017-03-15       Impact factor: 4.307

3.  Inhibition of IL-10 and TGF-β receptors on dendritic cells enhances activation of effector T-cells to kill cholangiocarcinoma cells.

Authors:  Chutamas Thepmalee; Aussara Panya; Mutita Junking; Thaweesak Chieochansin; Pa-Thai Yenchitsomanus
Journal:  Hum Vaccin Immunother       Date:  2018-02-21       Impact factor: 3.452

4.  Anti-cancer effect and gene modulation of ET-743 in human biliary tract carcinoma preclinical models.

Authors:  Caterina Peraldo-Neia; Giuliana Cavalloni; Marco Soster; Loretta Gammaitoni; Serena Marchiò; Francesco Sassi; Livio Trusolino; Andrea Bertotti; Enzo Medico; Lorenzo Capussotti; Massimo Aglietta; Francesco Leone
Journal:  BMC Cancer       Date:  2014-12-05       Impact factor: 4.430

Review 5.  Hepatitis C virus infection of cholangiocarcinoma cell lines.

Authors:  Nicola F Fletcher; Elizabeth Humphreys; Elliott Jennings; William Osburn; Samantha Lissauer; Garrick K Wilson; Sven C D van IJzendoorn; Thomas F Baumert; Peter Balfe; Simon Afford; Jane A McKeating
Journal:  J Gen Virol       Date:  2015-02-20       Impact factor: 3.891

Review 6.  Molecular Markers in the Pathogenesis of Cholangiocarcinoma: Potential for Early Detection and Selection of Appropriate Treatment.

Authors:  Cornelia Braicu; Claudia Burz; Ioana Berindan-Neagoe; Ovidiu Balacescu; Marcel Tantau; Victor Cristea; Alexandru Irimie
Journal:  Gastroenterology Res       Date:  2009-05-20

Review 7.  Transforming Growth Factor-Beta (TGFβ) Signaling Pathway in Cholangiocarcinoma.

Authors:  Panagiotis Papoutsoglou; Corentin Louis; Cédric Coulouarn
Journal:  Cells       Date:  2019-08-23       Impact factor: 6.600

8.  Clinicopathological and prognostic significance of epithelial mesenchymal transition-related protein expression in intrahepatic cholangiocarcinoma.

Authors:  Xing Yao; Xiang Wang; Zishu Wang; Licheng Dai; Guolei Zhang; Qiang Yan; Weimin Zhou
Journal:  Onco Targets Ther       Date:  2012-10-12       Impact factor: 4.147

9.  Determining the effect of transforming growth factor-β1 on cdk4 and p27 in gastric cancer and cholangiocarcinoma.

Authors:  Sung Ryol Lee; Jae Wook Shin; Hyung Ook Kim; Byung Ho Son; Chang Hak Yoo; Jun Ho Shin
Journal:  Oncol Lett       Date:  2012-11-13       Impact factor: 2.967

10.  Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.

Authors:  Ismaïl Hendaoui; Ahlem Lahmar; Luca Campo; Sihem Mebarki; Sandrine Bichet; Daniel Hess; Martin Degen; Nidhameddine Kchir; Leila Charrada-Ben Farhat; Rania Hefaiedh; Christian Ruiz; Luigi M Terracciano; Richard P Tucker; Lotfi Hendaoui; Ruth Chiquet-Ehrismann
Journal:  Front Immunol       Date:  2021-02-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.